Biotech Values

[mcbio]

Re: NVS' DEB025

I assume the expectation is that DEB025 would ultimately be used as part of an HCV cocktail and not as a monotherapy +/- SoC. Assuming three HCV classes will be the norm for a future HCV cocktail, what class is the most susceptible to being replaced by a cyclophilin inhibitor? PI? Nuke? NS5A inhibitor? Just trying to understand where this different class could fit into the equation of an HCV DAA combo.